Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
The FDA has legal clearance to approve Liquidia’s pulmonary arterial hypertension treatment Yutrepia after two recent court developments.
United Therapeutics starts litigation with FDA over rival Liquidia`s drug application
Liquidia said in an SEC filing Wednesday that it will “aggressively defend” against a potential new patent covering United Therapeutics’ treprostinil for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today a collaboration with Sandoz Inc. (Sandoz) and Mainbridge Health Partners LLC (Mainbridge) to support the development of a new subcutaneous pump for infusion of Treprostinil Injection, a generic form of Remodulin®, for which Liquidia has the exclusive rights to promote and commercialize with Sandoz.
The CEO & Director Of Liquidia Corporation Roger Jeffs, Has Just Spent US$244k Buying 2.6% More Shares
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin®, is now also available for subcutaneous (“SC”) administration to treat patients diagnosed with pulmonary arterial hypertension (“PAH”).
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)